Kevin Berry, MD
Interventional Cardiology · Methuen, MANPI 1487653861
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.0% of the total across 141 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 20 manufacturers, the largest accounting for just 15.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,036 and has fallen 76.0% since, to $248 in 2025. That places this record below the midpoint for interventional cardiology clinicians in MA, where the typical reported total is $3,030.
Across 141 payments — averaging $21.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$471
- Johnson & Johnson$469
- Pfizer$308
- AstraZeneca$261
- Novo Nordisk$243
- Amarin Pharma, Inc.$199
- plus $1K from 14 others
What the payments were for
- Food & beverage$2,94097%
- Education$913%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 22 | $471 |
| Johnson & Johnson | 16 | $469 |
| Pfizer | 9 | $308 |
| AstraZeneca(2 entities) | 17 | $261 |
| Novo Nordisk | 4 | $243 |
| Amarin Pharma, Inc. | 21 | $199 |
| Abbott | 6 | $164 |
| Amgen | 9 | $161 |
| E.r. Squibb & Sons, L.L.C. | 8 | $143 |
| Heartflow, Inc. | 1 | $135 |
| Boehringer Ingelheim | 6 | $102 |
| Sanofi-aventis U.S. LLC | 5 | $78 |
| Merck | 4 | $68 |
| Regeneron Healthcare Solutions, Inc. | 3 | $50 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $42 |
| Bardy Diagnostics, Inc. | 2 | $40 |
| Esperion Therapeutics, Inc. | 2 | $31 |
| Bayer | 2 | $29 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,030 in reported general payments places this provider in the 50th percentile of 128 interventional cardiology providers in Massachusetts.
See all interventional cardiology providers in Massachusetts →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 11 | $199 |
| Losartan Potassium | 13 | $92 |
| Amlodipine Besylate | 11 | $91 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Methuen
- Sudarshan ChatterjeeMethuen$4K
- Eric SecemskyBoston$1.2M
- Darshan DoshiBoston$730K
- Charles GibsonBoston$661K
- Duane PintoBoston$491K
- Robert YehBoston$412K
- Thomas PiemonteBurlington$330K
- Suzanne BaronBoston$274K
- Farouc JafferBoston$213K
- Joseph GarasicBoston$152K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.